Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

Drug Resistance Updates

Volumn 13, Issue 6, 2010, Pages 180-195

  Pfaller, M A ^a   Andes, D ^b   Diekema, D J ^a   Espinel Ingroff, A ^c   Sheehan, D ^d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

Broth microdilution; Clinical and Laboratory Standards Institute (CLSI); European Committee on Antimicrobial Susceptibility Testing; Fluconazole

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIUM ISOLATE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLAVISPORA LUSITANIAE; CLINICAL AND LABORATORY STANDARDS INSTITUTE; CROSS RESISTANCE; DISK DIFFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING; FUNGAL GENE; FUNGEMIA; FUNGUS MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; INTERMETHOD COMPARISON; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; SPECIES DIFFERENCE; WILD TYPE;

EID: 77957893941     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.09.002     Document Type: Article

References (116)

1. B.D. Alexander, W.A. Schell, J.L. Miller, G.D. Long, and J.R. Perfect Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole Transplantation 80 2005 868 871
2. D. Andes In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis Antimicrob. Agents Chemother. 47 2003 1179 1186 (Pubitemid 36368572)
3. D. Andes Pharmacokinetics and pharmacodynamics of antifungals Infect. Dis. Clin. North Am. 20 2006 679 697
4. D. Andes, and M. van Ogtrop Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model Antimicrob. Agents Chemother. 43 1999 2116 2120
5. D. Andes, A. Forrest, and A. Lepole Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans Antimicrob. Agents Chemother. 50 2006 2374 2383
6. D. Andes, A. Lepak, and J. Nett In vivo pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling Antimicrob. Agents Chemother. 50 2006 2384 2394
7. A. Antoniadou, H.A. Torres, R.E. Lewis, J. Thornby, G.P. Bodey, J.P. Tarrand, X.Y. Han, K.V. Rolston, A. Safdar, I.I. Raad, and D.P. Kontoyiannis Candidemia in a tertiary care center: in vitro susceptibility and its association with outcome of initial antifungal therapy Medicine 82 2003 309 321
8. M.C. Arendrup, G. Kahlmeter, J.L. Rodriguez-Tudela, and J.P. Donnelly Breakpoints for susceptibility testing should not divide wild-type distributions of important target species Antimicrob. Agents Chemother. 53 2009 1628 1629
9. S. Arikan, M. Akova, M. Hayran, O. Ozdemir, M. Erman, D. Gur, and S. Unal Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis Clin. Infect. Dis. 26 1998 903 908
10. Arthington-Skaggs, B.A.; Lee-Yang, W.; Ciblak, M.A.; Frade, J.P.; Brandt, M.E.; Hajjeh, R.A.; Harrison, L.H.; Sofair, A.N.; Warnock, D.W. for the Candidemia Active Surveillance Group, 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC endpoint determinations and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and non-trailing Candida isolates. Antimicrob. Agents Chemother. 46, 2477-2481.
11. J.W. Baddley, M. Patel, M. Jones, G. Cloud, A.C. Smith, and S.A. Moser Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia Diagn. Microbiol. Infect. Dis. 50 2004 119 124
12. J.W. Baddley, M. Pai, S.M. Bhavnani, S.A. Moser, and D.R. Andes Association of fluconazole pharmacodynamics with mortality in patients with candidemia Antimicrob. Agents Chemother. 52 2008 3022 3028
13. J.E. Bennett, K. Izumikawa, and K.A. Marr Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis Antimicrob. Agents Chemother. 48 2004 1773 1777
14. A. Borst, M.T. Raimer, D.W. Warnock, C.J. Morrison, and B.A. Arthington-Skaggs Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole Antimicrob. Agents Chemother. 49 2005 783 787
15. S. Brun, T. Berges, and P. Poupard Mechanism of azole resistance in petite mutants of Candida glabrata Antimicrob. Agents Chemother. 48 2004 1788 1796
16. A.S. Chau, C.A. Mendrick, and F.J. Sabatelli Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles Antimicrob. Agents Chemother. 48 2004 2124 2131
17. C.J. Clancy, V.L. Yu, A.J. Morris, D.R. Snydman, and M.H. Nguyen Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia Antimicrob. Agents Chemother. 49 2005 3171 3177
18. Clinical and laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A3 3rd ed. 2008 Clinical and Laboratory Standards Institute Wayne, PA
19. Clinical and laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; 3rd Informational Supplement, M27-S3 2008 Clinical and Laboratory Standards Institute Wayne, PA
20. Clinical and laboratory Standards Institute Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Standard M44-A2 2008 Clinical and Laboratory Standards Institute Wayne, PA
21. Clinical and laboratory Standards Institute Zone Diameter Interpretive Standards, Corresponding Minimal Inhibitory Concentration. (MIC) Interpretive Breakpoints and Quality Control Limits for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Informational Supplement, M44-S2 2007 Clinical and Laboratory Standards Institute Wayne, PA
22. C.D. Collins, G.A. Eschenouer, S.L. Salo, and O.W. Newton To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemia J. Clin. Microbiol. 45 2007 1884 1888
23. M. Cuenca-Estrella, W. Lee-Yong, M.A. Ciblak, B.A. Arthington-Skaggs, E. Mellado, D.W. Warnock, and J.L. Rodriguez-Tudela Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species Antimicrob. Agents Chemother. 46 2002 3644 3647
24. I. Cuesta, C. Bielza, P. Larronaga, M. Cuenca-Estrella, F. Laguna, D. Rodriguez-Pands, B. Almirante, A. Pahessa, and J.L. Rodriguez-Tudela Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing Antimicrob. Agents Chemother. 53 2009 2949 2954
25. I. Cuesta, C. Bielza, M. Cuenca-Estrella, P. Larranaga, and J.L. Rodriguez-Tudela Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI), and its comparison with those of the European Committee on Antimicrobial Susceptibility Testing. (EUCAST) Antimicrob. Agents Chemother. 54 2010 1541 1546
26. A. Espinel-Ingroff, F. Barchiesi, M. Cuenca-Estrella, M.A. Pfaller, M. Rinaldi, J.L. Rodriguez-Tudela, and P.E. Verweij International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole J. Clin. Microbiol. 43 2005 3884 3889
27. S. Ferrari, F. Ischer, D. Calabreses, B. Posteraro, M. Sanguinetti, G. Fadda, B. Rohde, C. Bauser, O. Bader, and D. Sanglard Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence PLoS Pathogens 5 2009 e1000268
28. R. Franz, S.L. Kelly, D.C. Lamb, D.E. Kelly, M. Ruhnke, and J. Morschhauser Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains Antimicrob. Agents Chemother. 42 1998 3065 3072
29. T. Fukuoka, D.A. Johnston, C.A. Winslow, M.J. de Groot, C. Bert, C.A. Hitchcock, and S.G. Filler Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei Antimicrob. Agents Chemother. 47 2003 1213 1219
30. K.W. Garey, M.P. Pai, K.J. Suda, R.S. Turpin, M.D. Rege, D.E. Mingo, and D.T. Bearden Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines Pharmacoepidemiol. Drug Safety 16 2007 919 927
31. M.A. Ghannoum, and L.B. Rice Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance Clin. Microbiol. Rev. 12 1999 501 517
32. S.M. Grant, and S.P. Clissold Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses Drugs 39 1990 877 916
33. J. Guinea, M. Sanchez-Somolinos, and O. Cuevas Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux pumps Med. Mycol. 44 2006 575 578
34. S. Hadley, J.A. Martinez, L. McDermott, B. Rapino, and D.R. Snydman Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients J. Antimicrob. Chemother. 49 2002 415 419
35. W.W. Hope, E.M. Billaud, J. Lestner, and D.W. Denning Therapeutic drug monitoring for triazoles Curr. Opin. Infect. Dis. 21 2008 580 586
36. G. Kahlmeter, D.F.J. Brown, F.W. Goldstein, A.P. McGowan, J.W. Mouton, A. Osterlund, A. Rodloff, M. Steinbakk, P. Urbaskova, and A. Vatopoulos European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria J. Antimicrob. Chemother. 52 2003 145 148
37. G. Kahlmeter, and D.F.J. Brown Harmonization of antimicrobial breakpoints in Europe-can it be achieved? Clin. Microbiol. News 26 2004 187 192
38. M.E. Klepser, E.J. Wolfe, R.N. Jones, C.H. Nightingale, and M.A. Pfaller Antifungal pharmacodynamic characterization of fluconazole and amphotericin B tested against Candida albicans Animicrob. Agents Chemother. 41 1997 1392 1395
39. M.J. Klevay, D.L. Horn, D. Neofytos, M.A. Pfaller, and D.J. Diekema Initial treatment and outcome of Candida glabrata versus C. albicans bloodstream infection Diagn. Microbiol. Infect. Dis. 64 2009 152 157
40. M. Laverdiere, R.G. Lalonde, J.G. Baril, D.C. Sheppard, S. Park, and D.S. Perlin Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis J. Antimicrob. Chemother. 57 2006 705 708
41. S.C. Lee, C.P. Fung, J.S. Huang, C.J. Tsai, K.S. Chen, H.Y. Chen, N. Lee, L.C. See, and W.B. Shieh Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole Antimicrob. Agents Chemother. 44 2000 2715 2718
42. X. Li, N. Brown, and A.S. Chau Changes in susceptibility to posaconazole in clinical isolates of Candida albicans J. Antimicrob. Chemother. 53 2004 74 80
43. J.L. Lopez-Ribot, R.K. McAtee, L.N. Lee, W.R. Kirkpatrick, T.C. White, D. Sanglard, and T.F. Patterson Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis Antimicrob. Agents Chemother. 42 1998 2932 2937
44. J.L. Lopez-Ribot, R.K. McAtee, S. Perea, W.R. Kirkpatrick, M.G. Rinaldi, and T.F. Patterson Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients Antimicrob. Agents Chemother. 43 1999 1621 1630
45. A. Louie, G.L. Drusano, P. Banerjee, Q.F. Liu, W. Liu, M. Kaw, H. Shayegonia, H. Tuber, and M.H. Miller Pharmacodynamics of fluconazole in a murine model of systemic candidiasis Antimicrob. Agents Chemother. 42 1998 1105 1109
46. A. Lupetti, F. Danesi, and M. Campa Molecular basis of resistance to azole antifungals Trends Mol. Med. 8 2002 76 81
47. D.M. MacCallum, A. Coste, F. Ischer, M.D. Jacobson, F.C. Odds, and D. Sanglard Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection Antimicrob. Agents Chemother. 54 2010 1476 1483
48. J.A. Maertens History of the development of azole derivatives Clin. Microbiol. Infect. 10 Suppl. 1 2004 1 10
49. S.S. Magill, C. Shields, C.L. Spears, N. Choti, and W.G. Merz Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy J. Clin. Microbiol. 44 2006 529 535
50. P. Marichal, H. Vanden Bossche, and F.C. Odds Molecular biological characterization of an azole-resistant Candida glabrata isolate Antimicrob. Agents Chemother. 41 1997 2229 2237
51. K.A. Marr, T.C. White, and J.A. van Burik Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation Clin. Infect. Dis. 25 1997 908 910
52. K.A. Marr, C.N. Lyons, T. Rustad, R.A. Bowden, and T.C. White Rapid transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR Antimicrob. Agents Chemother. 42 1998 2584 2589
53. Martel, C.M.; Parker, J.E.; Bader, O.; Weig, M.; Gross, U.; Warrilow, A.G.S.; Rolley, N.; Kelly, D.E.; Kelly, S.L. (2010) Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother.; published online ahead of print 23 August 2010.
54. C.M. Metzler, and R.M. DeHaan Susceptibility tests of anaerobic bacteria: statistical and clinical considerations J. Infect. Dis. 30 1974 588 594
55. G.P. Moran, D. Sanglard, and S.M. Donnelly Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis Antimicrob. Agents Chemother. 42 1998 1819 1830
56. T. Mori, M. Matsumura, and Y. Kanamaru Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to antifungal agents during therapy Clin. Infect. Dis. 25 1997 1470 1471
57. V. Moudgal, T. Little, D. Boikov, and J.A. Vazquez Multiechinocandin- and multitriazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis Antimicrob. Agents Chemother. 49 2005 767 769
58. F.S. Nolte, T. Parkinson, D.J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J.R. Wingard Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia Antimicrob. Agents Chemother. 44 1997 196 199
59. A. Orozco, L. Higgenbothom, C. Hitchcock, T. Parkinson, D. Falconer, A.S. Ibrahim, M.A. Ghannoum, and S.G. Filler Mechanisms of fluconazole resistance in Candida krusei Antimicrob. Agents Chemother. 42 1998 2645 2649
60. L. Ostrosky-Zeichner, J.H. Rex, P.G. Pappas, R.J. Hamill, R.A. Larsen, H.W. Horowitz, W.G. Powderly, N. Hyslop, C.A. Kauffman, J. Cleary, J.E. Mangino, and J. Lee Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrob. Agents Chemother. 47 2003 3149 3154
61. L. Ostrosky-Zeichner, J.H. Rex, M.A. Pfaller, D.J. Diekema, B.D. Alexander, D. Andes, S.D. Brown, V. Chaturvedi, M.A. Ghannoum, C.C. Knapp, D.J. Sheehan, and T.J. Walsh Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method Antimicrob. Agents Chemother. 52 2008 4175 4177
62. M.P. Pai, R.S. Turpin, and K.W. Garey Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia Antimicrob. Agents Chemother. 51 2007 35 39
63. A.A. Panackal, J.L. Gribskov, J.F. Staab, K.A. Kirby, M. Rinaldi, and K.A. Marr Clinical significance of azole antifungal drug cross-resistance in Candida glabrata J. Clin. Microbiol. 44 2006 1740 1743
64. Pappas, P.G.; Rex, J.H.; Sobel, J.D.; Filler, S.G.; Dismukes, W.E.; Walsh, T.J.; Edwards, J.E. from the Infectious Diseases Society of America, 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38, 161-189.
65. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin, T.F. Calandra, J.E. Edwards, S.G. Filler, J.F. Fisher, B.J. Kulhberg, L. Ostrosky-Zeichner, A.C. Reboli, J.H. Rex, T.J. Walsh, and J.D. Sobel Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin. Infect. Dis. 48 2009 503 535
66. M.D. Parkins, D.M. Sabuda, S. Elsayed, and K.B. Laupland Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections J. Antimicrob. Chemother. 60 2007 613 618
67. S. Perea, J.L. Lopez-Ribot, W.R. Kirkpatrick, R.K. McAtee, R.A. Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T.F. Patterson Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients Antimicrob. Agents Chemother. 45 2001 2676 2684
68. S. Perea, and T.F. Patterson Antifungal resistance in pathogenic fungi Clin. Infect. Dis. 35 2002 1073 1080
69. S. Perea, J. Lopez-Ribot, B.L. Wickes, W.R. Kirkpatrick, O.P. Dib, S.P. Bachmann, S.M. Keller, M. Martinez, and T.F. Patterson Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis Antimicrob. Agents Chemother. 46 2002 1695 1703 (Pubitemid 34535185)
70. M.A. Pfaller, J. Rhine-Chalberg, S.W. Redding, J. Smith, G. Farinacci, A.W. Fothergill, and M.G. Rinaldi Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis J. Clin. Microbiol. 32 1994 59 64
71. M.A. Pfaller, K.C. Hazen, S.A. Messer, L. Boyken, S. Tendolkar, R.J. Hollis, and D.J. Diekema Comparison of results of fluconazole disk diffusion testing for Candida species with results form a control reference laboratory in the ARTEMIS Global Antifungal Surveillance Program J. Clin. Microbiol. 42 2004 3607 3612
72. M.A. Pfaller, S.A. Messer, L. Boyken, C. Rice, S. Tendolkar, R.J. Hollis, and D.J. Diekema Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp J. Clin. Microbiol. 42 2004 3137 3141
73. M.A. Pfaller, L. Boyken, R.J. Hollis, S.A. Messer, S. Tendolkar, and D.J. Diekema In vitro susceptibilities of clinical isolates of Candida species Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods J. Clin. Microbiol. 43 2005 3807 3810
74. M.A. Pfaller, D.J. Diekema, and D.J. Sheehan Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing Clin. Microbiol. Rev. 19 2006 435 447
75. M.A. Pfaller, S.A. Messer, L. Boyken, R.J. Hollis, S. Tendolkar, and D.J. Diekema Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods J. Clin. Microbiol. 45 2007 70 75
76. M.A. Pfaller, and D.J. Diekema Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance J. Invasive Fungal Infect. 1 2007 74 92
77. Pfaller, M.A.; Diekema, D.J.; Gibbs, D.L.; Newell, V.A.; Meis, J.F.; Gould, I.M.; Fu, W.; Colombo, A.L.; Rodriguez-Noriega, E.; and the Global Antifungal Surveillance Study, 2007b. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5 year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45, 1735-1745.
78. M.A. Pfaller, S.A. Messer, L. Boyken, S. Tendolkar, R.J. Hollis, and D.J. Diekema Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a Global Antifungal Surveillance Program J. Clin. Microbiol. 46 2008 551 559
79. M.A. Pfaller, L.B. Boyken, R.J. Hollis, J. Kroeger, S.A. Messer, S. Tendolkar, and D.J. Diekema Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a Global Candida Antifungal Surveillance Program J. Clin. Microbiol. 46 2008 3585 3590
80. Pfaller, M.A.; Diekema, D.J.; Ghannoum, M.A.; Rex, J.H.; Alexander, B.D.; Andes, D.; Brown, S.D.; Chaturvedi, V.; Espinel-Ingroff, A.; Fowler, C.L.; Johnson, E.M.; Knapp, C.C.; Motyl, M.R.; Ostrosky-Zeichner, L.; Sheehan, D.J.; Walsh, T.J. For the Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee, 2009. Wild-Type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47, 3142-3146.
81. M.A. Pfaller, L. Boyken, R.J. Hollis, J. Kroeger, S.A. Messer, S. Tendolkar, R.N. Jones, J. Turnidge, and D.J. Diekema Wild-Type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp J. Clin. Microbiol. 48 2010 52 56
82. M.A. Pfaller, and D.J. Diekema Wild-Type MIC distributions and epidemiologic cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr. Fungal Infect. Reports 4 2010 168 174
83. B. Posteraro, M. Tumbarello, and M. La Sorda Azole resistance of Candida glabrata in a case of recurrent fungemia J. Clin. Microbiol. 44 2006 3046 3047
84. R.A. Proctor, C. von Eiff, and B.C. Kahl Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections Nat. Rev. Microbiol. 4 2006 295 305
85. S. Redding, J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis Clin. Infect. Dis. 18 1994 240 242
86. S.W. Redding, W.R. Kirkpatrick, S. Sarille, B.J. Coco, W. White, A. Fothergill, M. Rinaldi, T. Eng, T.F. Patterson, and J. Lopez-Ribot Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation J. Clin. Microbiol. 41 2003 619 622
87. J.H. Rex, J.E. Bennett, A.M. Sugar, P.G. Pappas, C.M. van der Horst, J.E. Edwards, R.G. Washburn, W.M. Scheld, A.W. Karchmer, A.P. Dine, M.J. Levenstein, and C.D. Webb A randomized trial comparing fluconazole and amphotericin B for the treatment of candidemia in patients without neutropenia N. Engl. J. Med. 331 1994 1325 1330
88. J.H. Rex, M.A. Pfaller, J.N. Galgiani, M.S. Bartlett, A. Espinel-Ingroff, M.A. Ghannoum, M. Lancaster, F.C. Odds, M.G. Rinaldi, T.J. Walsh, and A.L. Barry Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections Clin. Infect. Dis. 24 1997 235 247 (Pubitemid 127774263)
89. J.H. Rex, M.A. Pfaller, T.J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M.A. Ghannoum, L.L. Gosey, F.C. Odds, M.G. Rinaldi, D.J. Sheehan, and D.W. Warnock Antifungal susceptibility testing: practical aspects and current challenges Clin. Microbiol. Rev. 14 2001 643 658
90. J.H. Rex, and M.A. Pfaller Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35 2002 982 989
91. J.L. Rodriguez-Tudela, J.P. Donnelly, M.A. Pfaller, E. Chryssanthou, P. Warr, D.W. Denning, A. Espinel-Ingroff, F. Barchiesi, and M. Cuenca-Estrella Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E. Dis. 7. 1) and CLSI. (M27-A2) J. Clin. Microbiol. 45 2007 109 111
92. J.L. Rodriguez-Tudela, B. Almirante, D. Rodriguez-Pardo, F. Laguna, J.P. Donnelly, J.W. Mouton, A. Pahissa, and M. Cuenca-Estrella Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia Antimicrob. Agents Chemother. 51 2007 3599 3604
93. J.L. Rodriguez-Tudela, M.C. Arendrup, F. Barchiesi, J. Bille, E. Chryssanthou, M. Cuenca-Estrella, E. Dannaoui, D.W. Denning, J.P. Donnelly, F. Dromer, W. Fegeler, C. Lass-Florl, C. Moore, M. Richardson, P. Sandven, A. Vengrak, and P. Verweij EUCAST definitive document EDef7. 1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts Clin. Microbiol. Infect. 14 2008 398 405
94. J.L. Rodriguez-Tudela, J.P. Donnelly, M.C. Arendrup, S. Arikan, F. Barchiesi, J. Bille, E. Cryssanthou, M. Cuenca-Estrella, E. Dannaoui, D. Denning, W. Fegeler, P. Garrstad, N. Klimko, C. Lass-Florl, C. Moore, M. Richardson, A. Schmalseck, J. Stenderup, A. Velegraki, and P. Verweij EUCAST technical note on fluconazole Clin. Microbiol. Infect. 14 2008 193 195
95. F. Sabatelli, R. Patel, P.A. Mann, C.A. Mendrick, C.C. Norris, R. Hare, D. Loebenberg, T.A. Black, and P.M. McNicolas In vitro activity of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts Antimicrob. Agents Chemother. 50 2006 2009 2015
96. Sandven, P.; Beranger, L.; Digranes, A.; Hawkland, H.H.; Mannsaker, T.; Gausted, P.; and the Norwegian Yeast Study Group, 2006. Candidemia in Norway. (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44, 1977-1981.
97. D. Sanglard, K. Kuchler, F. Ischer, J.L. Pagami, M. Monod, and J. Bille Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters Antimicrob. Agents Chemother. 39 1995 2378 2386
98. D. Sanglard, F. Ischer, M. Monod, and J. Bille Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors Antimicrob. Agents Chemother. 40 1996 2300 2305
99. D. Sanglard, F. Ischer, M. Monod, and J. Bille Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene Microbiology 143 1997 405 416
100. D. Sanglard, F. Ischer, D. Calabrese, P.A. Majcherczyk, and J. Bille The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents Antimicrob. Agents Chemother. 43 1999 2753 2765
101. D. Sanglard, F. Ischer, and J. Bille Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata Antimicrob. Agents Chemother. 45 2001 1174 1183
102. D. Sanglard, and F.C. Odds Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences Lancet Infect. Dis. 2 2002 73 85
103. M. Sanguinetti, B. Posteraro, B. Fiori, S. Ranno, R. Torelli, and G. Fadda Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance Antimicrob. Agents Chemother. 49 2005 668 679
104. P. Sendi, M. Rohrbach, and P. Graber Staphylococcus aureus small colony variants in prosthetic joint infection Clin. Infect. Dis. 43 2006 961 967
105. D.J. Sheehan, C.A. Hitchcock, and C.M. Sibley Current and emerging azole antifungal agents Clin. Microbiol. Rev. 12 1999 40 79
106. S. Simjee, P. Silley, H.O. Werling, and R. Byweten Potential confusion regarding the term "resistance" in epidemiological surveys J. Antimicrob. Chemother. 61 2008 228 229
107. A.M. Tortorano, C. Kibbler, J. Peman, H. Bernhandt, L. Klingspor, and R. Grillot Candidemia in Europe: epidemiology and resistance Int. J. Antimicrob. Agents 27 2006 359 366
108. J. Turnidge, G. Kahlmeter, and G. Kronvall Statistical characterization of bacterial wild-type MIC value distributions and determination of epidemiological cut-off values Clin. Microbiol. Infect. 12 2006 418 425
109. J. Turnidge, and D.L. Paterson Setting and revising antibacterial susceptibility breakpoints Clin. Microbiol. Rev. 20 2007 391 408
110. P. Vandeputte, G. Larcher, and T. Berges Mechanisms of azole resistance in a clinical isolate of Candida tropicalis Antimicrob. Agents Chemother. 49 2005 4608 4615
111. P. Vaudaux, W.L. Kelley, and D.P. Lew Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat Clin. Infect. Dis. 43 2006 968 970
112. T.C. White Increased mRNA levels of ERG16 CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus Antimicrob. Agents Chemother. 41 1997 1482 1487
113. T.C. White The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14-alpha demethylase in Candida albicans Antimicrob. Agents Chemother. 41 1997 1488 1494
114. T.C. White, K.A. Marr, and R.A. Bowden Clinical, cellular, and molecular factors that contribute to antifungal drug resistance Clin. Microbiol. Rev. 11 1998 382 402
115. A.G. Wilson, S.T. Micak, and D.J. Ritchie A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia Clin. Therapeutics 27 2005 1228 1327
116. L. Xiao, V. Madison, and A.S. Chau Three-dimensional models of wild-type and mutated forms of cytochrome P450 14 alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding Antimicrob. Agents Chemother. 48 2004 568 574